Ro 31-7549 acetate

Protein Kinase C 19-31 acetate, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate

BA 1 acetate is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in v

BDC2.5 mimotope 1040-31 acetate is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. It can stimulate BDC2.5 cells with cells showing good response to this mimotope. 1040-31 peptide is specific for BDC2.5 TCR Tg+ (transgenic

PACAP-38 (31-38), human, mouse, rat acetate is an activator of PAC1 receptor. PACAP-38 (31-38), human, mouse, rat acetate demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production and can

TNF-α (31-45), human acetate is a peptide of tumor necrosis factor-α.

Endothelin-1 (1-31) (Human) acetate, a potent vasoconstrictor and hypertensive agent, is produced through the selective hydrolysis of big ET-1 by chymase [1].

Prolactin Releasing Peptide (1-31), human (acetate), is a potent GPR10 ligand with high affinity, eliciting prolactin secretion. It binds to human and rat GPR10 with K_i values of 1.03 nM and 0.33 nM, respectively, and serves as a tool for researching the hypothalamo-pituitary axis [1] [2].